Evaluation of $^{13}$C-urea breath test in the detection of Helicobacter pylori and in monitoring the effect of tripotassium dicitratobismuthate in non-ulcer dyspepsia


Abstract

Sixty nine patients with non-ulcer dyspepsia have been studied with endoscopy, biopsy, quick urease (CLO) test, Helicobacter pylori culture, and the $^{13}$C-urea breath test before and after treatment with tripotassium dicitratobismuthate (DeNol) two tablets daily for four weeks. Symptoms of non-ulcer dyspepsia were recorded using a standard questionnaire. Using $H$ pylori culture as the gold standard, the sensitivity of the $^{13}$C-urea breath test was 90%, the specificity 98-6%, and the accuracy 94-8% with a positive predictive value of 98.2% and a negative predictive value of 92.5%. Conversion rate from $H$ pylori positive to negative status after treatment with tripotassium dicitratobismuthate was 17-9%. Symptoms of non-ulcer dyspepsia improved appreciably after treatment irrespective of $H$ pylori status. The $^{13}$C-urea breath test is an accurate research tool suitable for serial testing and population surveys.

Spiral organisms on the mucosa of the human stomach have been noted sporadically since the last century, but interest was slight until 1983, when Marshall reported the first successful culture of Helicobacter pylori. Many reports have shown a high prevalence of $H$ pylori in patients with histological antral gastritis and duodenal ulcer, and a lower prevalence in gastric ulcer disease and in non-ulcer dyspepsia. These observations have led to a lively discussion of the possible aetiological role of $H$ pylori in these conditions. Present methods for detecting $H$ pylori comprise bacterial culture, urease tests, and histological examination of biopsy specimens; all of these are invasive and therefore not suitable for screening large populations or repeated testing of the same individuals. Serological tests are not invasive, but do not show unequivocally if active colonisation with $H$ pylori is present. Two recent reports suggest that the non-invasive $^{13}$C- or $^{14}$C-urea breath test provides a simple way to detect $H$ pylori colonisation without endoscopy and biopsy. These breath tests exploit the high urease activity of $H$ pylori in vivo and detect the CO$_2$ derived from labelled urea in expired breath. The aim of the present study was twofold. Firstly, we have attempted to measure the sensitivity and specificity of the $^{13}$C-urea breath test by comparison with culture of $H$ pylori from endoscopic antral biopsy specimens because published data pertaining to this point are not abundant. Secondly, we investigated the incidence of $H$ pylori, correlation with symptoms, the efficacy of clearing it with tripotassium dicitratobismuthate, and the rate of its recolonisation after clearance in a group of patients with non-ulcer dyspepsia.

Patients and methods

Consecutive outpatients aged 18–70 years referred for routine endoscopy because of ulcer-like symptoms (epigastric pain related to food and relieved by milk or antacids) were studied. Subjects were excluded if they had any endoscopically visible organic lesion of the upper alimentary tract, such as gastric or duodenal ulcer, cancer, macroscopic gastritis, duodenitis, or oesophagitis, or if they received drugs other than antacids during the previous two weeks. Patients with debilitating disease, previous gastric surgery, or renal insufficiency, or who were pregnant or breast feeding, or those who were unable to cooperate were also excluded. The study was approved by the Brent District Ethical Committee and all patients gave informed written consent.

ENDOSCOPY AND BIOPSY

Endoscopy was done one to five days before and within 48 hours of completing the treatment. Patients fasted for at least eight hours before the examination, which was performed with an Olympus GIF XQ10 fiberoptic panendoscope. Before reuse, the endoscope and the biopsy forceps were washed, cleaned, and soaked in glutaraldehyde solution (Cidex Solution* R, Arbrook, Inc, Arlington, Texas 76010) for 10 minutes and thoroughly washed again with sterilised water.

At endoscopy three antral biopsy specimens were taken for bacterial cultures, quick urease (CLO) test and a direct Gram stain.

CLO test

One specimen was used for the CLO test, a commercially available quick urease test kit, which was kept for three hours at about 30°C and after that at room temperature for one day. The test was examined half an hour, three hours, and 24 hours after biopsy, and if a definite pink colour developed at any of these times the test

Departments of Gastroenterology and Nutrition

S Dill
J J Payne-James
J J Misiewicz
G K Grimble

and Microbiology, Central Middlesex Hospital, London NW10 7NS
D McSwiggan
K Pathak

Department of Anatomy and Physiology, The University, Dundee DD1 4HN
A J Wood
C M Scrimgeour
M J Rennie

Correspondence to:
Dr J J Misiewicz.
Accepted for publication
18 December 1989
was considered to be positive for *H pylori*.

**Microbiology**

The remaining two biopsy specimens were placed in thiol-containing transport medium, transferred to the microbiological laboratory within two hours, and processed on receipt. Each biopsy specimen was cultured on chocolate-blood agar to which lincomycin, colistin, amphotericin B, and trimethoprim (Oxoid SR 95 selective supplement) and 1% vitox (Oxoid SR 90) had been added. Plates were placed at 37°C in an anaerobic jar in which a microaerophilic atmosphere was maintained by means of a Microaerophilic System Envelope (BBL CampyPak) and incubated for up to seven days. Growth was recorded semiquantitatively (up to 50 colonies=light growth; 51–200 colonies=moderate growth; >200=heavy growth). Organisms were identified as *H pylori* on the basis of morphology and biochemical tests. Smears were also prepared from each biopsy specimen and stained by Gram’s method. Smears showing typically spiral Gram negative organisms were reported as positive.

**13C-urea breath test**

The first 13C-urea breath test was done within five days of the initial endoscopy, but before treatment with tripotassium dicitratobismuthate was started, and repeated within three days after the end of four weeks’ treatment. Expired air was collected into 21 plastic bags fitted with a non-return inlet valve and a septum, through which gases were sampled over 5 s into 20 ml Vacutainers (Becton Dickinson, Rutherford, New Jersey, USA: Ref 606433). Duplicate baseline breath samples were taken from patients who had fasted overnight. Thereafter they swallowed 120 ml of a 31% (w/v) solution of nutrient-dense glucose polymer, which was made by diluting (Fortical, Cow & Gate Ltd, Tonbridge, Wiltshire) with distilled water. This was done to delay gastric emptying. Fifteen minutes later subjects swallowed 20 ml of water containing 250 mg 13C-urea (99%, Tracer Technologies Inc, Somerville, MA 02145, USA). Breath samples were collected at 10, 20, 30, 40, 60, 80, 100, and 120 minutes after the dose. Samples were subsequently analysed within two weeks of collection using a Finnigan MAT Delta D dual-inlet multicollector isotope ratio mass spectrometer, fitted with an automated breath gas analysis system.4 Total carbon dioxide production was measured by indirect calorimetry at standard time intervals relative to the 13C sample. The instantaneous tracer production in the breath was then calculated from the product of the CO₂ production rate and the mole fraction of tracer 13CO₂ at each sampling time point. The breath test results were expressed as follows: (a) Atom Percentage Excess (APE) of the post-dose samples relative to the mean of the two pre-dose samples; (b) the cumulative percentage dose of tracer recovered in the breath. This was calculated as 100×the mole fraction of tracer derived 13C in the expired CO₂. APE is conceptually equivalent to the specific activity of a radioactive tracer. Thus for each post-dose breath sample, the 13C enrichment was calculated relative to the mean natural abundance of 13CO₂ in the pre-dose samples, expressed as APE relative to natural abundance. APE is analogous to specific activity as used to measure radioactive tracer enrichment, but using a stable isotope tracer, account must be taken of the natural abundance of the tracer isotope, so that APE is a measure of the mole fraction of tracer-derived CO₂ in the expired breath CO₂. The APE was calculated from the mass spectroscopic observations by standard methods.5 The instantaneous rate of appearance of tracer in the breath is thus the product of APE/100 and the CO₂ production rate. The cumulative % dose of tracer recovered in the breath was obtained by integrating the instantaneous tracer production curve over the appropriate time period, and expressing this as a molar percentage of the 13C-urea given.

In the absence of labelled urea, the Fortical meal results in a small increase in the 13C content of the expired CO₂, presumably from maize-derived carbohydrate in the meal. This cannot be distinguished from 13CO₂ derived from labelled urea, and results in enrichments of about 0-005 APE after one to two hours, and an apparent % dose recovered of one to two after this time. The magnitude of this apparent % dose recovered depends on the 13C content of the subject’s diet as well as the 13C content of the meal. To allow for the normal interindividual variation in baseline breath 13C content, the cut off between positive and negative tests was set at 3% of the dose recovered after two hours. It might be possible to increase the sensitivity of the test to low levels of *H pylori* infection by using a meal with a lower 13C content. Using the 3% cut off, no negative test had an APE >0-01 at 20 minutes, while in positive tests the APE ranged from >0-01 to 0-15 at 20 minutes.

**Conduct of study**

After the initial breath test the patients were treated with tripotassium dicitratobismuthate as DeNoltabs, two twice daily, given on an empty stomach 30 minutes before meals for four weeks; this dosage provides bismuth 480 mg/day. No other medication apart from an antacid (Gelusil tablets, 0-58 g aluminium-silicahydrate per tablet) was allowed. Before treatment patients were questioned in a standardised manner about five predefined symptoms: daytime or night time epigastric pain, nausea or vomiting, heartburn, and postprandial discomfort defined as fullness, belching, distension, or regurgitation occurring after a meal. The presence of each symptom was scored as: 0 absent; 1 recalled on direct questioning; 2 present, but not impairing activities; 3 interfering with daily work and life. Frequency of symptoms was scored as: 1 one or less day per week; 2 several times each week; 3 daily. The symptom scores of presence and frequency of each symptom were added for each patient giving a possible score ranging from 0 to 30. After completing four weeks’ treatment, and before the second endoscopy which was performed within 48 hours after the end of treatment, patients were asked identical questions by
an investigator unaware of the patient's *H. pylori* status. The second endoscopy with biopsies, and the second breath test were done on the same or on the following day, respectively. Patients with a negative breath test after four weeks' treatment with tripotassium dicitratobismuthate underwent a third breath test four weeks later.

Compliance with tripotassium dicitratobismuthate treatment was assessed by interview and by returned tablet count at the end of treatment: return tablet count below 10 tablets (out of 120 dispensed) was considered to indicate good compliance. Side effects were also inquired about at the second interview.

All completed tests independent of tripotassium dicitratobismuthate compliance were used for the analysis of the power of the 13C-urea breath test, but analysis of the symptoms and of the efficacy of tripotassium dicitratobismuthate was only done on the patients who completed the treatment with it as well as the pre- and post-treatment endoscopies, biopsies, and breath tests.

Statistical analysis of the results was done using the U-test (Wilcoxon, Mann, and Whitney). Differences were considered significant at p<0·05.

Results

13C-urea breath test

Sixty nine patients, 35 men (mean age 38·7 years, range 18–70 years) and 34 women (mean age 45·3 years, range 23–68 years), entered the study; 65 completed all tests. The four dropouts were one woman who developed influenza at the time of follow up endoscopy, another woman who declined the second breath test, and two men who declined the second endoscopy. Thus 134 complete examinations were available for analysis of the breath test: 69 endoscopies, biopsy specimens with culture, CLO, and breath tests before treatment and 65 after treatment with tripotassium dicitratobismuthate.

A summary of all the test results is given in Table I.

**Table I** Comparison of all H pylori detection tests with culture results

<table>
<thead>
<tr>
<th>Culture</th>
<th>60 positive</th>
<th>74 negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLO test</td>
<td>54 (1 false positive)</td>
<td>80 (7 false negative)</td>
</tr>
<tr>
<td>Gram stain</td>
<td>51 (0 false positive)</td>
<td>83 (11 false negative)</td>
</tr>
<tr>
<td>Breath test</td>
<td>55 (1 false positive)</td>
<td>79 (6 false negative)</td>
</tr>
</tbody>
</table>

**Table II** Results in free patients with false-negative 13C-urea breath tests immediately after treatment

<table>
<thead>
<tr>
<th>Test</th>
<th>Before tripotassium dicitratobismuthate (n)</th>
<th>After tripotassium dicitratobismuthate (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Culture</td>
<td>Heavy (5)</td>
<td>Light (3)</td>
</tr>
<tr>
<td></td>
<td>Moderate (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heavy (1)</td>
<td></td>
</tr>
<tr>
<td>Gram stain</td>
<td>Positive (5)</td>
<td>Negative (4)</td>
</tr>
<tr>
<td></td>
<td>Positive (1)</td>
<td></td>
</tr>
<tr>
<td>CLO test</td>
<td>Positive at 30 min (5)</td>
<td>Positive at 3 h (1)</td>
</tr>
<tr>
<td></td>
<td>Negative (1)</td>
<td>Negative at 24 h (4)</td>
</tr>
<tr>
<td>Breath test</td>
<td>Positive (5)</td>
<td>Negative (5)</td>
</tr>
</tbody>
</table>

13C-urea breath test before treatment

Breath tests recorded before treatment with tripotassium dicitratobismuthate correlated better with *H. pylori* culture than those recorded after treatment. Thus, before treatment *H. pylori* culture was positive in 34 and negative in 35 patients. Breath test was positive in 33 and negative in 36 patients, showing only one false negative result (Figure, Table III).

**Table III** 13C-urea breath test

<table>
<thead>
<tr>
<th>Sensitivity</th>
<th>% Overall</th>
<th>% Before tripotassium dicitratobismuthate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specificity</td>
<td>99·6</td>
<td>100·0</td>
</tr>
<tr>
<td>Accuracy</td>
<td>95·8</td>
<td>98·5</td>
</tr>
<tr>
<td>Positive predictive value</td>
<td>98·2</td>
<td>100·0</td>
</tr>
<tr>
<td>Negative predictive value</td>
<td>97·5</td>
<td>97·2</td>
</tr>
</tbody>
</table>
dyspepsia, giving a prevalence rate of 49-3%. Using the breath test, 33 H pylori positive patients were found, giving a prevalence rate of 47-8%—showing closely similar results with the two methods. The H pylori positive patients (n = 28) were older (mean (SEM) 44-8 (2-12) years) than the rest (n = 34; 39-1 (2-22) years; p < 0.05).

**EFFECT OF TRIPOTASSIUM DICITRATOBSMUTHATE ON H PYLORI STATUS**

Thirty four of the 35 H pylori negative and 28 of the 34 H pylori positive patients complied with tripotassium dicitratobismuthate treatment and completed all the requirements of the trial protocol. Six (four men) H pylori positive patients (two did not attend for second endoscopy; three stopped tripotassium dicitratobismuthate treatment because of headache (one), nausea (one), or tiredness (one); one took only half the dose) and one H pylori negative patient (one woman did not attend for second endoscopy) were excluded from the analysis.

In the 28 positive patients all three tests became negative after tripotassium dicitratobismuthate treatment in only five (18%). All three tests became weakly positive in a further nine (32%) of compliant patients. In the remainder (n = 14; 50%), results of the three tests remained unchanged despite four weeks’ treatment with tripotassium dicitratobismuthate. 13C-urea breath tests were positive again in four of the five negative patients who attended for the third breath test one month after completing treatment.

**CORRELATION BETWEEN H PYLORI STATUS AND SYMPTOMS**

There was no significant difference in the pre-treatment mean (SEM) symptom score between the H pylori positive (n = 28; score 18-4 (0-6)) and negative patients (n = 34; score 20-1 (0-8)). The symptom score decreased significantly (p < 0.05) in both groups of patients, but the mean final scores were almost identical (post-treatment mean (SEM) score H pylori positive 8-1 (1-0); negative 8-7 (1-0)).

**Discussion**

The present results suggest that the 13C-urea breath test is a sensitive and highly specific method for non-invasive detection of H pylori. Presumably because of decreased numbers of H pylori, and therefore a lower quantity of urease, the 13C-urea breath test was slightly less sensitive immediately after treatment with tripotassium dicitratobismuthate. Similar findings have been reported by Weil and colleagues. We therefore recommend in future studies with drugs active against H pylori either repeating the test four weeks after the end of treatment, as was done in this study, or using the 13C-urea breath test only a few weeks after completion of treatment. The 13C-urea breath test compares well with the 13C-urea breath test. Other workers using the 13C-urea breath test have reported similar values for sensitivity and specificity to those from this study. This is not surprising, as the 13C and 14C tests are conceptually similar. The great advantage, however, of the 13C-urea breath test is the absence of radiation risk. This makes the 13C-urea breath test suitable for serial studies and population surveys, or for studies in children and women who are at risk of, or are, pregnant. The 13C test is particularly suitable for epidemiological investigations and for longterm follow up, essential for monitoring the response to treatment with helicobacteridical agents. Our data suggest that the 13C-urea breath test may be simplified to only four breath samples: two baseline samples and single samples after 30 and 60 minutes.

Non-ulcer dyspepsia is generally diagnosed in patients with symptoms suggesting the presence of a peptic ulcer, but in whom no ulcer is found at endoscopy. Little is known about the pathogenesis of this syndrome and treatment is often ineffective. Results of this study confirm previous reports indicating that H pylori is detected in about half the patients with non-ulcer dyspepsia and that the H pylori positive patients tend to be older. The latter finding corresponds well with serological data, which show a progressively increasing incidence of H pylori antibodies with age. We found that improvement of symptoms was independent of H pylori status. In a trial comparing bismuth, erythromycin, and placebo, McNulty et al found symptomatic improvement in all three groups. There was a trend towards greater improvement of symptoms in those treated with bismuth, and in those cleared of H pylori, but these trends were not statistically significant. There was no placebo group in the present study, so it is possible that the symptomatic improvement recorded was due to some other action of tripotassium dicitratobismuthate, independent of its effect on H pylori. Other workers were also unable to find correlation between symptoms of non-ulcer dyspepsia and the presence of H pylori. In contrast, Rokkas et al reported appreciable symptomatic improvement in H pylori positive patients with non-ulcer dyspepsia treated with colloidal bismuth for eight weeks. The reasons for this discrepancy remain unclear.

Various clearance rates are reported by others using the same treatment scheme with tripotassium dicitratobismuthate 240 mg twice daily for four weeks. In this study all detection methods were negative after treatment in only
18% of the initially positive patients, and it is now generally accepted that bismuth 480 mg/day produces poor clearance rates for H. pylori. In those patients breath tests became positive again one month after treatment, suggesting either suppression, rather than eradication of H. pylori, or reinfection. Similar findings have been reported by others. Restriction endonuclease DNA analysis suggests that recrudescence of H. pylori, rather than reinfection, causes the rapid return to positivity. The results of this study show good accuracy and specificity of the 13C-urea breath test, and suggest that the symptoms of non-ulcer dyspepsia do not correlate with H. pylori status.

S Dill was supported by a grant from the Swiss National Science Foundation.

1 Bizzozero G. Ueber die schlauchtörmigen drusen des magendarmkanals und die beziehung ihres epithels zu dem oberflächenepithel der schleimhaut. Arch Mikrosch Akad 1893; 42:82-152.
Evaluation of 13C-urea breath test in the detection of Helicobacter pylori and in monitoring the effect of tripotassium dicitratobismuthate in non-ulcer dyspepsia.


*Gut* 1990 31: 1237-1241
doi: 10.1136/gut.31.11.1237

Updated information and services can be found at:
http://gut.bmj.com/content/31/11/1237

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

*Dyspepsia* (297)

**Notes**